RxDoctor Payments Data

Sarah Burke

Rheumatology · Michigan City, INNPI 1568849396

Payments from drug & device makers

$2,119in general payments, 2019–2025

Across 108 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$269
  • AstraZeneca$193
  • Boehringer Ingelheim$177
  • Genentech USA, Inc.$113
  • GSK$81
  • plus $227 from 8 others

What the payments were for

  • Food & beverage$1,74682%
  • Education$37318%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,119 in reported general payments places this provider in the 40th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$67,601
Medicare patients
220
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab47$529,311
Enbrel SureclickEtanercept40$304,857
RinvoqUpadacitinib43$297,766
BenlystaBelimumab42$221,620
Orencia ClickjectAbatacept34$198,435
Taltz AutoinjectorIxekizumab22$153,603
Enbrel MiniEtanercept14$103,274
Actemra ActpenTocilizumab28$100,491
OtezlaApremilast17$94,885
Taltz SyringeIxekizumab12$81,913
SimponiGolimumab11$63,791
Hydroxychloroquine Sulfate302$11,667
MethotrexateMethotrexate Sodium335$6,906
SavellaMilnacipran Hcl12$6,818
Cevimeline Hcl28$4,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$1,061$304,58455 claims
GSKBenlysta$81$221,62042 claims
AmgenOtezla$60$94,88517 claims
Johnson & JohnsonSimponi$269$63,79111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →